216 related articles for article (PubMed ID: 31130632)
1. The Oxidative Pathway to Dopamine-Protein Conjugates and Their Pro-Oxidant Activities: Implications for the Neurodegeneration of Parkinson's Disease.
Wakamatsu K; Nakao K; Tanaka H; Kitahori Y; Tanaka Y; Ojika M; Ito S
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31130632
[TBL] [Abstract][Full Text] [Related]
2. The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson's disease.
Nagatsu T; Nakashima A; Watanabe H; Ito S; Wakamatsu K; Zucca FA; Zecca L; Youdim M; Wulf M; Riederer P; Dijkstra JM
J Neural Transm (Vienna); 2023 May; 130(5):611-625. PubMed ID: 36939908
[TBL] [Abstract][Full Text] [Related]
3. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species.
Spencer JP; Jenner P; Daniel SE; Lees AJ; Marsden DC; Halliwell B
J Neurochem; 1998 Nov; 71(5):2112-22. PubMed ID: 9798937
[TBL] [Abstract][Full Text] [Related]
4. Neuromelanin in Parkinson's Disease: Tyrosine Hydroxylase and Tyrosinase.
Nagatsu T; Nakashima A; Watanabe H; Ito S; Wakamatsu K
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456994
[TBL] [Abstract][Full Text] [Related]
5. Metal-catalyzed oxidation of protein-bound dopamine.
Akagawa M; Ishii Y; Ishii T; Shibata T; Yotsu-Yamashita M; Suyama K; Uchida K
Biochemistry; 2006 Dec; 45(50):15120-8. PubMed ID: 17154550
[TBL] [Abstract][Full Text] [Related]
6. Protective and toxic roles of dopamine in Parkinson's disease.
Segura-Aguilar J; Paris I; Muñoz P; Ferrari E; Zecca L; Zucca FA
J Neurochem; 2014 Jun; 129(6):898-915. PubMed ID: 24548101
[TBL] [Abstract][Full Text] [Related]
7. Drug treatment of Parkinson's disease. Time for phase II.
Drukarch B; van Muiswinkel FL
Biochem Pharmacol; 2000 May; 59(9):1023-31. PubMed ID: 10704931
[TBL] [Abstract][Full Text] [Related]
8. Riddles in the dark: Decoding the relationship between neuromelanin and neurodegeneration in locus coeruleus neurons.
Iannitelli AF; Weinshenker D
Neurosci Biobehav Rev; 2023 Sep; 152():105287. PubMed ID: 37327835
[TBL] [Abstract][Full Text] [Related]
9. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease.
Gerlach M; Double KL; Ben-Shachar D; Zecca L; Youdim MB; Riederer P
Neurotox Res; 2003; 5(1-2):35-44. PubMed ID: 12832223
[TBL] [Abstract][Full Text] [Related]
10. Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease.
Zhang F; Dryhurst G
J Med Chem; 1994 Apr; 37(8):1084-98. PubMed ID: 7909337
[TBL] [Abstract][Full Text] [Related]
11. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease.
Zucca FA; Segura-Aguilar J; Ferrari E; Muñoz P; Paris I; Sulzer D; Sarna T; Casella L; Zecca L
Prog Neurobiol; 2017 Aug; 155():96-119. PubMed ID: 26455458
[TBL] [Abstract][Full Text] [Related]
12. Modifications of the iron-neuromelanin system in Parkinson's disease.
Fasano M; Bergamasco B; Lopiano L
J Neurochem; 2006 Feb; 96(4):909-16. PubMed ID: 16417570
[TBL] [Abstract][Full Text] [Related]
13. Neuromelanin selectively induces apoptosis in dopaminergic SH-SY5Y cells by deglutathionylation in mitochondria: involvement of the protein and melanin component.
Naoi M; Maruyama W; Yi H; Yamaoka Y; Shamoto-Nagai M; Akao Y; Gerlach M; Tanaka M; Riederer P
J Neurochem; 2008 Jun; 105(6):2489-500. PubMed ID: 18399961
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, redox properties, in vivo formation, and neurobehavioral effects of N-acetylcysteinyl conjugates of dopamine: possible metabolites of relevance to Parkinson's disease.
Shen XM; Xia B; Wrona MZ; Dryhurst G
Chem Res Toxicol; 1996; 9(7):1117-26. PubMed ID: 8902266
[TBL] [Abstract][Full Text] [Related]
15. Oxidative stress: a role in the pathogenesis of Parkinson's disease.
Götz ME; Freyberger A; Riederer P
J Neural Transm Suppl; 1990; 29():241-9. PubMed ID: 2193108
[TBL] [Abstract][Full Text] [Related]
16. Glutathione, iron and Parkinson's disease.
Bharath S; Hsu M; Kaur D; Rajagopalan S; Andersen JK
Biochem Pharmacol; 2002 Sep; 64(5-6):1037-48. PubMed ID: 12213603
[TBL] [Abstract][Full Text] [Related]
17. The enigma of neuromelanin in Parkinson's disease substantia nigra.
Youdim MB; Ben-Shachar D; Riederer P
J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
[TBL] [Abstract][Full Text] [Related]
18. Glutathione redox status in mitochondria and cytoplasm differentially and sequentially activates apoptosis cascade in dopamine-melanin-treated SH-SY5Y cells.
Naoi M; Yi H; Maruyama W; Inaba K; Shamoto-Nagai M; Akao Y; Gerlach M; Riederer P
Neurosci Lett; 2009 Nov; 465(2):118-22. PubMed ID: 19737600
[TBL] [Abstract][Full Text] [Related]
19. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?
Herrera A; Muñoz P; Steinbusch HWM; Segura-Aguilar J
ACS Chem Neurosci; 2017 Apr; 8(4):702-711. PubMed ID: 28233992
[TBL] [Abstract][Full Text] [Related]
20. Dopamine, Oxidative Stress and Protein-Quinone Modifications in Parkinson's and Other Neurodegenerative Diseases.
Monzani E; Nicolis S; Dell'Acqua S; Capucciati A; Bacchella C; Zucca FA; Mosharov EV; Sulzer D; Zecca L; Casella L
Angew Chem Int Ed Engl; 2019 May; 58(20):6512-6527. PubMed ID: 30536578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
